These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 25064467)
1. PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia. Pedersen CS; Sørensen DB; Parachikova AI; Plath N Behav Brain Res; 2014 Oct; 273():63-72. PubMed ID: 25064467 [TBL] [Abstract][Full Text] [Related]
2. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance. Pedersen CS; Goetghebeur P; Dias R J Neurosci Methods; 2009 Dec; 185(1):66-9. PubMed ID: 19761795 [TBL] [Abstract][Full Text] [Related]
3. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. Neill JC; Harte MK; Haddad PM; Lydall ES; Dwyer DM Eur Neuropsychopharmacol; 2014 May; 24(5):822-35. PubMed ID: 24287012 [TBL] [Abstract][Full Text] [Related]
5. Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review. Grayson B; Barnes SA; Markou A; Piercy C; Podda G; Neill JC Curr Top Behav Neurosci; 2016; 29():403-428. PubMed ID: 26510740 [TBL] [Abstract][Full Text] [Related]
6. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189 [TBL] [Abstract][Full Text] [Related]
7. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Enomoto T; Noda Y; Nabeshima T Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation. Snigdha S; Neill JC Behav Brain Res; 2008 Mar; 187(2):489-94. PubMed ID: 18037171 [TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Guidali C; Viganò D; Petrosino S; Zamberletti E; Realini N; Binelli G; Rubino T; Di Marzo V; Parolaro D Int J Neuropsychopharmacol; 2011 Feb; 14(1):17-28. PubMed ID: 20196921 [TBL] [Abstract][Full Text] [Related]
11. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia. Mastropaolo J; Rosse RB; Deutsch SI Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637 [TBL] [Abstract][Full Text] [Related]
12. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265 [TBL] [Abstract][Full Text] [Related]
14. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709 [TBL] [Abstract][Full Text] [Related]
15. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Mouri A; Noda Y; Enomoto T; Nabeshima T Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558 [TBL] [Abstract][Full Text] [Related]
16. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Nabeshima T; Mouri A; Murai R; Noda Y Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514 [TBL] [Abstract][Full Text] [Related]
17. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Cochran SM; Kennedy M; McKerchar CE; Steward LJ; Pratt JA; Morris BJ Neuropsychopharmacology; 2003 Feb; 28(2):265-75. PubMed ID: 12589379 [TBL] [Abstract][Full Text] [Related]
18. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012 [TBL] [Abstract][Full Text] [Related]
19. A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. McLean SL; Beck JP; Woolley ML; Neill JC Behav Brain Res; 2008 May; 189(1):152-8. PubMed ID: 18282619 [TBL] [Abstract][Full Text] [Related]
20. [Neuropsychopharmacological study on an animal model for negative symptom of schizophrenia induced by repeated phencyclidine treatment]. Noda Y; Nabeshima T Yakugaku Zasshi; 2000 Aug; 120(8):677-82. PubMed ID: 10946617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]